2Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in earlystage uterine sarcoma: a Gynecologic Oncology Group study. Cancer,1993,71 (Suppl): 1702-1709.
3Arrastia CD, Fruchter RG, Clark M, et al. Uterine carcinosarcomas:incidence and trends in management and survival. Gynecol Oncol, 1997,65:158-163.
4Trudy RB, Steven P, Haluk C, et al. Prospective trial of cisplatin,adriamycin, and dacarbazine in metastatic mixed mesodermal sarcoma of the uterus and ovary. Am J Clin Oncol, 1991,14:246-250.
5Bodner AB, Bondner K, Obermair A, et al. Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Anticancer Res, 2001, 21(4B):3069-3084.
6Fujii H, Yoshida M, Gong ZX, et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res, 2001, 60(1):114-120.
7McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer, 2002,12(6):687-690.
8Micci F, Teixeira MR, Haugom L, et al. Genomic aberration in carcinosarconma of the uterine corpus. Genes Chromosomes Cancer,2004, 40(3):229-246.
9Yoshida Y, Kurokawa T, Fukuno N, et al. Markers of apoptosis and angiogenesis indicate that carcinomatous components play an important role in the malignant behavior of uterine carcinosarcoma.Hum Pathol, 2000, 31(12):1448-1454.
10Amant F, Cadron I, Fuso L, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol, 2005, 98(2):274-280.
3Huang C, Sun Z, Sun Y, et al. Association of increased ligand cy- clophilin A and receptor CD147 with hypoxia, angiogenesis, me- tastasis and proguosis of tongue squamous cell carcinoma [ J ]. Histopathology,2012,60 (5) :793-803.
4Horiuchi A, Hayashi T, Kikuchi N, et al. Hypoxia upregulates ov- grian cancer invasiveness via the binding of HIF-1 c to a hypoxia- induced,methylation-I hypoxia response element of $100A4 gene [J]. Int J Cancer,2012,131 (8) :1755-1767.
5Masleanikova AV, Orlova AG, Prianikova TI, et al. Clinical signif- icance and diagnostic methods for tumoral hypoxia [ J ]. Vopr Onkol,2011,57(4) :413-420.
6Wu D, Zhang R, Zhao R, et 'al. A Novel Function of Novobicin: disrupting the interaction of HIF la and p300/CBP through direct binding to the H1F-lc C-Terminal activation domain [ J ]. PLoS One,2013,8(5) : e62014.
7Diers AR, Vayalil PK, 01iva CR, et al. Mitochondria! bioenerget- ics of metastatic breast cancer cells in response to dylmmic chan- ges in oxygen tension:effects of HIF-1 a[ J]. PLoS One,2013,8 (6) :1371.
